Correspondence cornelia.halin@pharma.ethz.ch In Brief T cell migration through afferent lymphatic vessels contributes to immune surveillance, but the cellular mechanisms of this process are largely unknown. Using intravital microscopy, Teijeira et al. show that T cells crawl in an ICAM-1/LFA-1-dependent manner within inflamed dermal lymphatic capillaries but only flow with lymph once in contracting collectors.
SUMMARY
T cells are the most abundant cell type found in afferent lymph, but their migration through lymphatic vessels (LVs) remains poorly understood. Performing intravital microscopy in the murine skin, we imaged T cell migration through afferent LVs in vivo. T cells entered into and actively migrated within lymphatic capillaries but were passively transported in contractile collecting vessels. Intralymphatic T cell number and motility were increased during contact-hypersensitivity-induced inflammation and dependent on ICAM-1/LFA-1 interactions. In vitro, blockade of endothelial cell-expressed ICAM-1 reduced T cell adhesion, crawling, and transmigration across lymphatic endothelium and decreased T cell advancement from capillaries into lymphatic collectors in skin explants. In vivo, T cell migration to draining lymph nodes was significantly reduced upon ICAM-1 or LFA-1 blockade. Our findings indicate that T cell migration through LVs occurs in distinct steps and reveal a key role for ICAM-1/LFA-1 interactions in this process.
INTRODUCTION
Afferent lymphatic vessels (LVs) fulfill important immune functions by transporting soluble antigen and leukocytes such as dendritic cells (DCs) or recirculating T cells to draining lymph nodes (dLNs). T cells represent the major leukocyte cell type found in steady-state afferent lymph (Mackay et al., 1990; Young, 1999) , and their migration through peripheral tissues and into afferent LVs is thought to contribute to immune surveillance. Most T cells found in afferent lymph of sheep and humans display a memory phenotype, with CD4 + T cells outnumbering CD8 + T cells by $4-to 5-fold (Mackay et al., 1990; Yawalkar et al., 2000) . The factors that determine T cell residence as compared to tissue egress into afferent LVs are not completely clear, but various studies have demonstrated that the CCR7/CCL21 pathway (Bromley et al., 2013; Debes et al., 2005) and sphingosine-1-phosphate (S1P) (Brown et al., 2010; Ledgerwood et al., 2008 ) play a pivotal role in this process. Recently, the phenotype of recirculating memory CD4 + T cells (T RCM ) was described as CCR7 T RCM were shown to migrate from skin to dLNs and from there back into circulation and to sites of cutaneous inflammation (Bromley et al., 2013) .
Intravital microscopy (IVM) has recently shed light on the motility of individual T cells in peripheral tissues like the skin. In particular, IVM studies have revealed that under inflammatory conditions, both CD4
+ and CD8 + effector T cells actively migrate in the dermis (Egawa et al., 2011) . Conversely, in the memory phase following an antiviral immune response, CD8 + cells were shown to remain arrested in the epidermis, whereas CD4 + memory cells avidly migrated through the dermis (Gebhardt et al., 2011) . In contrast to interstitial migration, T cell entry into afferent LVs and tissue exit has thus far not been investigated by IVM. In this study, we describe a mouse model that allows for simultaneous visualization of endogenous T cells and LVs by IVM. Using this model, we observed that T cells migrate in a semi-directed manner within afferent lymphatic capillaries and are carried away by flow once they have reached downstream collecting vessels. Moreover, we demonstrate that during inflammation, intralymphatic T cell crawling and migration to dLNs depend on ICAM-1 and LFA-1.
RESULTS

Characterization of the Mouse Model
To visualize T cell migration within LVs, we crossed Prox1-GFP mice, which express GFP under the control of the lymphatic-specific Prox1 promoter (Choi et al., 2011) Figure 1B ). In intravital confocal imaging performed in murine ear skin, both GFP + LVs and DsRed hi T cells were brightly fluorescent ( Figure 1C ). To image under inflammatory conditions, we elicited a contact hypersensitivity (CHS) response toward oxazolone. This led to a striking increase in the number of intra-and extravascular DsRed hi T cells ( Figure 1D ). Also in inflamed skin, DsRed hi cells were mainly CD8 + and CD4 + T cells displaying an effector-memory phenotype ( Figures 1A and 1B) . Inflammation also induced the recruitment of a population of DsRed lo cells into the skin ( Figure S1C ). DsRed lo cells displayed a larger side scatter (SSC-A) and were negative for CD3, CD11c, and Ly6G but positive for CD11b and NK1.1 ( Figure S1C ), suggesting that these were natural killer (NK) cells. 
T Cells Crawl within Lymphatic Capillaries and Flow within Lymphatic Collectors
We next imaged intravasation of DsRed hi T cells into LVs in CHS-inflamed ear skin ( Figure 1E ; Movie S4). T cell intravasation preferentially occurred in areas close to the blind ends of lymphatic capillaries, as described for DCs (Pflicke and Sixt, 2009) . Once within dermal lymphatic capillaries, T cells moved by active crawling, as previously described for intralymphatic DCs (Nitschké et al., 2012; Russo et al., 2016; Tal et al., 2011) (Figure 1F; Movies S2 and S3) . To visualize the behavior of T cells within lymphatic collectors, we imaged near the base of the ear pinnae, where mostly collector vessels are present. Here, we observed T cells crawling in lymphatic segments and subsequently getting detached and passively drawn into the collector upon collector pumping ( Figure 1G ; Movie S5). Using faster acquisition settings, we observed T cells flowing within pumping afferent LVs in the ear (Movie S6). To further visualize T cells in efferent LVs, we imaged the efferent LV leaving the inguinal LN by stereomicroscopy. In this large collector, the passive movement of T cells was synchronized with the pumping of the collector, and the valves largely impeded back flow of T cells ( Figure 1H ; Movie S7). The average T cell speed was $180 mm/s, but peak velocities of up to 1 mm/s were reached in the valve regions. Overall, these experiments revealed that T cell migration to dLNs involves entry at the level of the lymphatic capillaries, active crawling and patrolling within capillaries, and passive flow once the cells reach contracting collecting vessels ( Figure 1I ).
Inflammation Increases T Cell Motility within LVs
In agreement with previous IVM studies (Overstreet et al., 2013) , interstitial T cell motility in steady state was rather low ( in CHS-induced tissue inflammation, the motility of DsRed hi T cells increased in the interstitium and even more so within lymphatic capillaries (Figures 2A-2C ; Movie S3). Increases in T cell motility appeared to be a consequence of tissue inflammation, since it was also observed in inflammation induced by injection of complete Freund's adjuvant (CFA) (Figures S2A-S2C ).
T Cell Motility within Lymphatic Vessels of Inflamed Skin Is ICAM-1 and LFA-1 Dependent We and others have previously shown that ICAM-1 is upregulated in LVs during CHS-and CFA-induced skin inflammation (Johnson et al., 2006; Vigl et al., 2011) . This prompted us to investigate whether ICAM-1 was involved in the increase in intralymphatic T cell motility observed in the context of inflammation. Interestingly, we found that ICAM-1 levels were consistently higher in lymphatic endothelial cells (LECs) derived from lymphatic capillaries than in LECs derived from collecting vessels and thus in the vessel segment in which T cells and DCs move by active crawling ( Figures 3A and 3B ). Since ICAM-1 mediates T cell crawling on blood vascular endothelium (Shulman et al., 2009; Steiner et al., 2010) , we next investigated whether ICAM-1 blockade would affect T cell crawling within inflamed lymphatic capillaries. While no change in the motility of interstitial T cells was observed upon ICAM-1 blockade, the speed and motility coefficient of intralymphatic T cells were reduced to values previously measured in uninflamed, steady-state conditions ( Figures 3C, 3D , and 2A, and 2B). We also noticed that T cells migrating within LVs in CHS-inflamed ears displayed the characteristic shape of a cell migrating in an integrin dependent fashion, i.e., an evident uropod and a leading edge ( Figure 3E ). In contrast, intralymphatic T cells in non-inflamed ears or upon ICAM-1 blockade, displayed a more rounded shape ( Figures 3E and 3F ). Further IVM experiments revealed that blockade of LFA-1 (i.e., the T cell-expressed ligand of ICAM-1) resulted in a comparable reduction of intralymphatic T cell crawling, suggesting the requirement of ICAM-1/LFA-1 interactions in this process ( Figures 3G and 3H) .
To investigate whether ICAM-1 blockade would impact the overall ability of T cells to advance through the lymphatic network, we performed experiments with in vitro Th1-polarized DsRed + effector T cells (Gó mez et al., 2015) ( Figures S3A-S3C) in ear skin explants of Prox1-GFP mice. In our setup, Th1 cells were added on the peripheral ear skin region of the explant and left to enter into the underlying lymphatic capillaries in presence of anti-ICAM-1 or control immunoglobulin G (IgG). When analyzing the more centrally located collecting vessels 24 hr later, we consistently detected fewer T cells within collectors of anti-ICAM-1-treated as compared to control-treated explants, suggesting that ICAM-1 blockade had interfered with T cell advancement from their point of entry at the level of the lymphatic capillaries into the collectors (Figures S3D-S3H ).
ICAM-1 Blockade Impairs T Cell Crawling, Adhesion, and Transmigration In Vitro To further validate our findings, we established an in vitro assay system involving Th1 cells and conditionally immortalized murine LECs (imLECs) (Vigl et al., 2011) ( Figures S3A-S3C and S4A) . Also in vitro, Th1 cell motility on lymphatic endothelium was significantly reduced upon ICAM-1 blockade ( Figures 4A and  4B) . Surprisingly, T cells crawled equally fast on resting and on tumor necrosis factor alpha/interferon gamma (TNF-a/IFN-g)-treated imLEC monolayers, likely because imLECs, in contrast to LECs in the skin, already express high levels of ICAM-1 under resting conditions ( Figure S4A ). Although TNF-a/IFN-g treatment induced a strong upregulation of VCAM-1 in imLECs (Figure S4A ), VCAM-1 blockade did not further reduce the speed of T cell crawling under inflammatory conditions ( Figures S4B  and S4C ). Similarly, IVM performed in the presence of VCAM-1 blocking antibody (6C7.1) did not reveal any contribution of VCAM-1 to intralymphatic crawling ( Figure S4F ). ICAM-1 reportedly mediates leukocyte extravasation from blood vessels (Shulman et al., 2009; Steiner et al., 2010) as well as DC migration through LVs (Johnson et al., 2006; Teijeira et al., 2013) . We therefore next investigated whether ICAM-1 also promoted effector T cell adhesion and transmigration across lymphatic endothelium. Under control conditions, ICAM-1 blockade strongly inhibited T cell adhesion (Figure 4C) . By contrast, under TNF-a/IFN-g-treated conditions, when VCAM-1 was highly upregulated (Figure S4A ), combined ICAM-1/VCAM-1 blockade was needed to profoundly inhibit T cell adhesion to LECs ( Figure 4C ). Conversely, in in vitro transmigration assays, ICAM-1 blockade equally inhibited Th1 transmigration across resting or TNF-a/IFN-g-treated imLEC monolayers ( Figure 4D ), without any further contribution of VCAM-1 to the transmigration process ( Figures S4D  and S4E ).
ICAM-1 or LFA-1 Blockade Reduces T Cell Migration from Inflamed Skin to dLNs
Finally, we assessed the overall relevance of ICAM-1 in in vivo T cell migration through afferent LVs to dLNs. For this, we co-injected activated T cells and ICAM-1 blocking or control antibody into CHS-inflamed ear skin and quantified T cell numbers in the dLN 18 hr later. In this setup ICAM-1 blockade significantly reduced T cell migration to the dLN ( Figures 4E and 4F) . Similarly, blockade of LFA-1 significantly reduced the number of adoptively transferred T cells that migrated to the dLN ( Figures  4G and 4H) . Overall, these findings demonstrate a key role for ICAM-1/LFA-1 interactions in T cell migration through afferent LVs.
DISCUSSION
In this study, we imaged T cell migration into and within dermal LVs. In contrast to T cell extravasation from blood vessels or migration within the skin, this process is far less well understood, at both the molecular and cellular levels. Our results show that T cell migration through afferent LVs occurs in a stepwise fashion; T cells that have entered into afferent capillaries first crawl in a semi-directed manner toward lymphatic collectors, from where they are passively transported within the lymph fluid to the dLN. This multistep process recapitulates the multistep migration pattern that we and others recently described for DC migration through afferent lymphatics (Nitschké et al., 2012; Russo et al., 2016; Tal et al., 2011) . The reason why DCs and T cells need to actively crawl within afferent capillaries probably lies in the weak lymph flow conditions within these vessels segments. Most likely, only the pumping lymphatic collectors generate sufficient flow and shear to support passive transport of leukocytes at high speed within lymph fluid. However, given that anesthesia is expected to slow down lymph flow, T cell speeds measured in collectors of anesthetized animals may be an underestimation of T cell speeds in collectors of awake animals. In agreement with our previous findings on DC migration (Russo et al., 2016) , T cells do not migrate unidirectionally through capillaries but display an intralymphatic patrolling behavior. Whether this intralymphatic movement is indeed semi-directed, and as in the case of DCs, dependent on an intralymphatic CCL21 gradient (Russo et al., 2016) remains to be investigated. Under steady-state conditions, we typically observed only few T cells in the interstitium or within afferent capillaries and collectors. Given that most dermal T cells display an effector-memory phenotype, this low cell number most likely represents an artifact of the hygienic mouse housing conditions of laboratory mice, in which abnormally few effector-memory cells populate peripheral tissues (Beura et al., 2016) . It is therefore very likely that under less hygienic, more natural conditions, many more T cells are present within afferent lymphatics in steady state. By contrast, under inflammatory conditions, high numbers of T cells are recruited into the skin and into afferent LVs. This is consistent with afferent lymph cannulation studies in sheep reporting a dramatic increase in T cell entering the afferent lymph during inflammation (Brown et al., 2010) . Our data show that the striking increase in intralymphatic crawling velocity observed in vivo in the context of inflammation was mainly due to ICAM-1 upregulation in LECs; blockade of ICAM-1 or its T cell-expressed ligand, LFA-1, reduced crawling velocities to values observed under steady-state conditions, during which LECs express low levels of ICAM-1. Besides mediating intralymphatic crawling, ICAM-1 also supported T cell adhesion and transmigration across LEC monolayers and, most importantly, the overall process of T cell migration to dLNs. Notably, we observed the contribution of ICAM-1 to T cell migration to dLNs under inflammatory conditions, but not under steady-state conditions (data not shown), likely because of the low ICAM-1 levels expressed on LVs in the absence of inflammation. Our observations are in agreement with previous findings on DCs, which migrate integrin independently into lymphatics and to dLNs in steady state (Lä mmermann et al., 2008) , whereas in inflammation, integrins and their LECexpressed ligands start to play a key role in migration (Johnson et al., 2006; Johnson and Jackson, 2010; Teijeira et al., 2013) . In agreement with our in vitro findings, we did not observe any effect of VCAM-1 blockade on in vivo T cell crawling within capillaries ( Figures S4F and S4G) . However, blockade of VCAM-1 strongly reduced the overall ability of T cells to migrate from inflamed skin to the dLN ( Figures S4G and S4H) . Although not experimentally addressed in this study, these findings point toward an involvement of VCAM-1 in T cell entry into LVs in vivo.
In support of such an involvement, we observed that combined blockade of VCAM-1 and ICAM-1 further reduced in vitro Th1 cell adhesion to lymphatic endothelium when compared to ICAM-1 blockade alone ( Figure 4C ). However this experiment did not address the contribution of VCAM-1 alone to in vitro adhesion. The reason why VCAM-1 blockade did not result in a defect in in vitro transmigration ( Figures S4D and S4E ) could be linked with the fact that in-vitro-generated Th1 cells expressed rather low levels of the a4 integrin subunit CD49d, which forms part of the VCAM-1-binding VLA-4 integrin ( Figure S3C ). Additionally, in-vitro-cultured imLECs express very high ICAM-1 levels (Figure S4A ), which might have overridden any potential contribution of VCAM-1 in the transmigration process.
Overall, our data reveal that LFA-1/ICAM-1 interactions are not only important for directing T cells out of blood vessels into peripheral tissues but also facilitate T cell tissue egress and recirculation during inflammation. These findings somewhat differ from those recently reported for T cell egress from LNs; here, LFA-1 and ICAM-1 were shown to prevent T cell transmigration across lymphatic sinuses into efferent lymphatics, thereby contributing to a longer T cell dwell time within the LN (Reichardt et al., 2013) . The reason for these differences between the roles of LFA-1/ ICAM-1 in T cell migration into afferent versus efferent lymphatics is not clear, but it could be related to the different functions and localization of the tissue egress and retention signals S1P and CCL21 in LNs and skin. In inflammatory and malignant conditions, tissue egress of T cells most likely takes place almost exclusively via afferent LVs. Given that the molecular players in LV entry and crawling are very similar to those involved in tissue entry from blood vessels, these mechanisms are very difficult to dissect from a therapeutic point of view. It is likely that approved drugs such as fingolimod (a functional antagonist of S1P receptors) or natalizumab (a monoclonal antibody blocking a4 integrin subunits) not only affect entry but also exit of T cells from inflamed tissues. Thus far, only two lymphatic endothelial cell-expressed adhesion molecules mediating T cell migration through afferent LVs have been identified, namely CLEVER-1 (Karikoski et al., 2009 ) and the macrophage mannose receptor (Salmi et al., 2013) . Overall, our study contributes to understanding the molecular control of T cell migration into afferent lymphatics and adds insight on how this process occurs at the cellular level.
EXPERIMENTAL PROCEDURES Mouse Strains
Wild-type (WT) C57BL/6 mice were purchased from Janvier. Prox1-GFP mice (Choi et al., 2011) and hCD2-DsRed mice (Veiga-Fernandes et al., 2007) were bred in our facility. All experiments were approved by the Cantonal Veterinary Office Zurich.
Flow Cytometry
Flow cytometry was performed on ear skin, LNs, spleen, or in-vitro-generated Th1 cells from CD2-DsRed or WT mice. Ear skin was digested with collagenase IV (Invitrogen) as previously described (Vigl et al., 2011) . Single-cell suspensions were stained as specified in Supplemental Experimental Procedures. Fluorescence-activated cell sorting (FACS) analysis was performed on a BD FACSCanto (BD Biosciences) using FACSDiva software. Data were analyzed offline using FlowJo software 10.0.1 (Tree Star).
IVM Specifications and Treatment Conditions
IVM on the dorsal side of the mouse ear pinna of anesthetized hCD2-DsRedxProx1-GFP mice was performed as previously described (Nitschké et al., 2012; Russo et al., 2016) . The exact IVM specifications, treatment conditions, and specifications for T cell motility analysis are provided in Supplemental Experimental Procedures.
CHS-Induced Ear Skin Inflammation
A CHS response toward oxazolone was induced as described previously (Vigl et al., 2011) . Briefly, mice were anesthetized and sensitized by topical application of 2% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazoline-5-one; Sigma) in acetone/olive oil (4:1 vol/vol) on the shaved abdomen (50 mL) and on each paw (5 mL). 5 days later, 10 mL of a 1% oxazolone solution was applied topically to each side of the ears (challenge phase). Experiments were performed 24 hr after challenge.
Adoptive Transfer Experiment
CD4
+ cells were purified from the spleens of OTII mice using CD4 (L3T4) microbeads (Miltenyi Biotec). CD4 + T cells were activated for 48 hr with 100 ng/mL OVA 323-339 peptide. After an additional 24 hr without peptide, cells were labeled with CFSE (Sigma) according to the manufacturer's instructions. 10 6 cells, together with 5 mg anti-mouse ICAM-1 antibody (clone YN1/1.7.4; BioLegend), anti-mouse LFA-1 antibody (clone M17/4; BioXCell), anti-mouse VCAM-1 (6C7.1; Engelhardt et al., 1998) , or corresponding isotypes (from BioLegend or BioXCell), in 10 mL were co-injected into the dorsal half of CHS-inflamed ears of WT mice. 18 hr later, auricular LNs were harvested, stained with CD4-APC (BioLegend), and analyzed on a FACSCalibur (BD Biosciences). Counting beads were added to determine absolute cell numbers.
Generation of Th1 Cells CD4 + cells were isolated from LNs and spleen of hCD2-DsRed mice and differentiated into Th1 cells in vitro as described previously (Gó mez et al., 2015) and in Supplemental Experimental Procedures.
In Vitro Experiments with Murine LECs and Th1 Cells
For details, see Supplemental Experimental Procedures.
Statistical Analysis
All cell-tracking data are presented as medians, and all other results are presented as mean plus SEM. Datasets were analyzed with Prism 6 (GraphPad). Kruskal-Wallis test followed by post hoc analysis was used for multiple comparisons and Mann-Whitney U test for simple comparisons.
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